OspA on a spirochete, injected by tick, and OspA in LYMErix, injected by syringe, BOTH caused neuro-Lyme, which is post-sepsis syndrome. So they changed the case definition to exclude the neuro cases and get the “vaccine” approved. LYMErix is long gone, but ticks are still maiming people with OspA, and the victims cannot get diagnosed because of the fake testing. End of story.

Research was falsified. Research was done in Europe to avoid automatic publication in the U.S. They lied in published journal articles. They fraudulently changed the case definition. CDC officers stood to profit from the vaccines and a monopoly on tick-borne-disease test kits. They knowingly gave a toxic “vaccine” to thousands of trial participants and sold it to unsuspecting consumers. That’s just the tip of the iceberg.

What they did constitutes FRAUD, FALSE CLAIMS, RACKETEERING, ASSAULT and HOMICIDE.

THE SICKEST PEOPLE CANNOT GET DIAGNOSED BECAUSE THESE GREEDY BASTARDS WANTED TO PROFIT FROM A VACCINE THAT WAS NOT A VACCINE AT ALL, BUT THE CAUSE OF NEURO-LYME. THEY KNEW IT, SO THEY RIGGED THE TESTING TO HIDE THE TRUTH.

Furthermore, they have for 20 years waged a campaign of disinformation against the public (fully supported by the CDC) and a SMEAR CAMPAIGN against their victims, who cannot get help from anyone and are dying–some slowly and some quickly.

No doctor, not even any so-called “Lyme-Literate” MD, knows how to treat the neurological outcome of OspA poisoning, because it is a disease of permanent immunosuppression.

That’s all you need to know about Lyme disease.

WHO PARTICIPATED in the TWO OspA VACCINE TRIALS:

ALL of them lied in their journal reports on both vaccines.

LYMErix
http://www.nejm.org/doi/pdf/10.1056/NEJM199807233390401

Allen Steere, Vijay Sikand, Christopher Schmid (CDC officer), Francois Meurice, Dennis Parenti (SKB), Erol Fikrig (Yale, owns the patent), Robert Schoen (Yale), John Nowakowski, David Krause, Charles Buscarino, Sabine Laukamp, Henry Feder, Michael Caldwell (tried to force all NY school children to get LYMErix), etc., see the Vaccine Study Group (see below).
ImmuLyme
http://www.nejm.org/doi/full/10.1056/NEJM199807233390402

The complete list of authors is as follows: L.H. Sigal, M.D., J.M. Zahradnik, M.D., P. Lavin, Ph.D., S.J. Patella, M.S.N., N.P.-C., G. Bryant, M.D., R. Haselby, D.O., E. Hilton, M.D., M. Kunkel, M.D., D. Adler-Klein, M.D., T. Doherty, M.D., J. Evans, M.D., S.E. Malawista, M.D., P. Molloy, M.D., A. Seidner, M.D., J. Sabetta, M.D., H.J. Simon, M.D., M.S. Klempner, M.D., J. Mays, Ph.D., and D. Marks, M.D. (Marks was the only one who reported any  neurological adverse events.)

Supported by Pasteur Mérieux Connaught.
We are indebted to the members of the data and safety monitoring board: Arthur Weinstein, M.D. (chairman), George Washington School of Medicine, Washington, D.C.; Cynthia Aranow, M.D., State University of New York Health Science Center at Brooklyn, Brooklyn; Dennis Clements, M.D., Ph.D., Duke University Medical Center, Durham, N.C.; Stuart Cook, M.D., University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark; Paul Fawcett, Ph.D., Alfred I. DuPont Institute, Wilmington, Del.; Neil Goldberg, M.D., White Plains, N.Y.; Stefan Gravenstein, M.D., East Virginia Medical School, Norfolk; John S. Lambert, M.D., Institute of Human Virology, University of Maryland at Baltimore, Baltimore; Sam Miller, M.D., University of Washington School of Medicine, Seattle; Steven Padula, M.D., University of Connecticut Health Center, Farmington; Andrew R. Pachner, M.D., Georgetown University Hospital, Washington, D.C.; Alexander M. Walker, M.D., Ph.D., Harvard School of Public Health, Boston; and Alan G. Barbour, M.D., University of California at Irvine, Irvine; to Maria Aguero-Rosenfeld, M.D., New York Medical College, Valhalla, for performance of Western blots; to Susan Wood, Pasteur Mérieux Connaught, Marnes La Coquette, France, for editorial advice and assistance; to Margaret Marshall, M.D., Pasteur Mérieux Connaught, Swiftwater, Pa., for editorial advice; to Damon Anthony, Robert Klepadlo, and Linda Petro, R.N., Pasteur Mérieux Connaught, Swiftwater, Pa., for clinical research; and to the following associate investigators: Michael F. Parry, M.D., and Gavin X. McLeod, M.D., Stamford Hospital, Stamford, Conn.; Gary S. Schlecter, M.D., Robert G. Hindes, M.D., Karim Nazir, M.D., and Paul B. Iannini, M.D., Danbury Hospital, Danbury, Conn.; Gregory J. Kundrat, M.D., and William A. Barcus, M.D., Southeastern Connecticut Medical Associates, Old Saybrook; Robert T. Simon, M.D., Physicians Research Center, Toms River, N.J.; Guy P. Fiocco, M.D., Jack M. Lockhart, M.D., and Peter A. Valen, M.D., Gundersen Medical Foundation, LaCrosse, Wis.; Thomas M. Richards, D.O., Ivan B. Schaller, M.D., Bardo Sanchez, Jr., M.D., Douglas M. DeLong, M.D., and Gerald W. Grim, M.D., Marshfield Clinic, Marshfield, Wis.; and Linda Taylor and Kathleen Corcoran, Boston Biostatistics, Boston.
Authur Weinstein was supposed to be the data safety monitor for this one but he clearly never looked at the data since soon thereafter, Lenny Sigal published with Dave Persing that the blots were unreadable.

Here are Sigal and Persing saying the Western Blots in both OspA vaccine trials were totally UNREADABLE (both use Mardx test strips) meaning no one at all could ever tell if someone had Lyme or not, meaning the entire trial was useless:

“The manufacturer of the only currently FDA-approved (and released) recombinant OspA Lyme disease vaccine has suggested that vaccination does not interfere with serological evaluation of Lyme disease in vaccine recipients—a statement that is not supported by the data presented here.”

https://cid.oxfordjournals.org/content/31/1/42.long

APPENDIX: LYME DISEASE VACCINE STUDY GROUP:
In addition to the authors, members of the Lyme Disease Vaccine Study Group were as follows: New England sites: Connecticut — S. Cohen, J. Boyer, K. Hanrahan, Clinical Research Consultants, Trumbull; P. Dalgin, J. Dalgin, A. Garrett, M. Petelaba, Fairfield County Lyme Vaccine Study, Stamford; H. Feder, S. Good, University of Connecticut Health Center, Farmington; J. Green, K. Miller, M. Spiegel, G. Daniel, R. Jacob, Arthritis Associates of Connecticut–New York, Danbury; E. Maderazo, M. Maiora- no, Norwich; A. Seidner, L. Bruno, Middlesex Hospital, Middletown; P. Sikand, N. Grills, B. Burnham, R. Albrecht, W. Beason, C. Jaskiewicz, East Lyme; C. DiSabitino, C. Brunet, J. Kenney, J. Craft, K. Pecerillo, T. Deshefy-Longhi, Yale University, New Haven; Maine — R. Smith, P. Rand, M. Holman, E. Lacombe, Maine Medical Center Research Institute, South Portland; Massachusetts — R. Hoxsie, D. Enos, P. Lindgren, S. Kendall, Martha’s Vineyard Hospital, Oak Bluffs; T. Lepore, C. Bartlett, C. Flahove, Public Health Associates of Nantucket, Nantucket; L. Marcus, M. Meharg, Travelers Health and Immunization Services, Newton; P. Molloy, M. Molloy, Jordan Hospital, Plymouth; G. Tratt, J. Johnson, Travel Clinic of Cape Cod, Hyannis; T. Treadwell, M. Heller, M. Cormier, Metro West Medical Center, Framingham; Rhode Island — P. Brassard, S. Brassard, Block Island; D. Mikolich, R. Perry, L. Haughey, J. Pezzulo, Omega Medical Re- search, Providence; J. Toder, C. Dessert, C. Brown, Johnston; P. Wood, W. Damle, J. Kropp, University of Rhode Island, Kingston; Mid-Atlantic sites: Delaware — W. Holloway, K. Haver, D. Ferris, R. Bidwell, Medical Center of Delaware, Wilmington; Maryland — B. Schwartz, C. Anderson, J. Hildreth, Innovative Medical Research, Towson; New Jersey — A. Kelsey, K. Kovacs, V. Mueller, Whitehouse Station Family Medicine, Whitehouse Station; New York — M. Caldwell, S. Marks, L. Squires, Dutchess County Health Department, Poughkeepsie; E. Grunwaldt, M. Lang, Shelter Island; E. Hilton, P. Rindos, Long Island Jewish Medical Center, New Hyde Park; G. Wormser, D. Holmgren, C. DiVenti, S. Welliver, D. McKenna, K. O’Keefe, New York Medical College, Valhalla; Pennsylvania — B. Bock, R. Lorraine, T. Fiorillo, D. Wichert, Harleysville Medical Associates, Harleysville; M. Lopatin, C. Pritchard, C. Franklin, R. Andrews, D. Grezlak, Center for Arthritis and Back Pain, Willow Grove; R. Nieman, P. Bankes, J. Kelly, R. Dee, S. Sridharan, T. Braun, Associates in Infectious Diseases, Abington; S. Topkis, C. Collins, Warminster Medical Associates, Warminster; Midwest sites: Wisconsin — J. Harrison, S. Donatell, North Woods Community Health Center, Minong; B. Sullivan, J. Krause, Marshfield Medical Research and Education Foundation, Marshfield; New England Medical Center, Boston: E. Taylor (data management), V. Melvin (secretary), G. McHugh (laboratory director), S. Doveikis (PCR testing), J. Paulhus, D. Carlson (serologic testing); Other medical centers: R. Ryan, P. Diaz, University of Connecticut, Farmington; S. Cretella, M. Breitenstein, Yale University School of Medicine, New Haven, Conn. (initial screening of samples); Kendle/gmi, Munich, Germany: A. Neiss, S Kiederle, E. Sennewald (data management and statistical analyses); Data and safety monitoring board: N. Halsey (director), School of Hygiene and Public Health, Johns Hopkins University School of Medicine, Baltimore; D. Dennis, Lyme Disease Program at Centers for Disease Control, Fort Collins, Colo.; C. Hoke, Jr., Walter Reed Army Medical Center, Bethesda, Md.; D. Rahn, Medical College of Georgia, Augusta; L. Moulton (statistician), Johns Hopkins School of Hygiene and Public Health, Baltimore; SmithKline Beecham Pharmaceuticals, Collegeville, Pa., and Rixensart, Belgium: T. Mayewski (research monitoring); C. Frazier, A. Grossman, K. Harl, B. Harte, J. MacDonald, K. McLeod, J. Miller, P. Murphy, J. Shirley, K. Stiede, J. Tarasar, M. Weigert (clinical research associates); D. Cory, M. Crayne, C. Hicks, L. Naeder, C. Pufko, H. Rathfon, E. Slavish, J. Stalica, D. Verity (project management and data management); D. Fu (project manager); C. Van Hoecke, M. Gillet (clinical and statistical support); Y. Lobet, P. Voet, D. DeGrave (preclinical and laboratory testing); M. Comberbach, B. Champluvier, P. Desmons, K. De Heyder, C. Capiau, M. Coste, B. Colau, G. Vanden Bossche (quality control and vaccine supplies).

DEARBORN RINGLEADERS:

https://badlymeattitude.com/wp-content/uploads/2015/02/dearborn_pdf.pdf

Complete charge sheets here: ChargeSheets_Complete_170313

Categories: Activism, Lyme Disease

Tags: CDC, immunosuppression, Lyme, LYMErix, NIH, OspA, sepsis, Steere, vaccines, yale